Earnings recap · ABBV
AbbVie Q3 2026 results
What AbbVie reported for Jul to Sep 2026, compared with the same quarter a year earlier, from the press release it filed with the SEC.
Source The press release AbbVie filed with the SEC on Oct 30, 2026 as Exhibit 99.1 to a Form 8-K (Item 2.02). The quarterly report (10-Q), with full financial statements and notes, hadn't been filed when this page was built. This page will say so here when it is.
The headline numbers
AbbVie reported net revenues of $17.4B for Q3 2026, compared with $15.8B a year earlier (+10.3%). Net earnings to AbbVie was $4.2B, compared with $186M (+2167.7%), and diluted earnings per share were $2.37, compared with $0.10. These are GAAP figures, prepared under the standard accounting rules. How EPS is calculated.
Comparing Q3 2026 (Jul to Sep 2026) with Q3 2025 (Jul to Sep 2025)
Each pair of bars shows both periods. Longer bar, more money. Bars in a group share one scale.
Q3 2026Q3 2025
Revenue and profit (GAAP)
Per share (GAAP)
| Line | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Net revenues | $17,404M | $15,776M | +10.3% |
| Operating income | $6,267M | $1,904M | +229.1% |
| Net earnings to AbbVie | $4,218M | $186M | +2167.7% |
| Diluted EPS | $2.37 | $0.10 | +2270.0% |
Change is worked out by Ticker Sage from the two figures shown. Operating margin, operating income as a share of revenue, was 36.0% compared with 12.1%. What profit margins measure.
What management said
"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio"
What to look for in the 10-Q
The press release has the headline tables. The 10-Q adds the full statements, the notes and management's discussion, including:
- Segment detail. Revenue and profit by business, and the reasons the company gives for changes.
- Items the adjusted measures leave out. Where those charges sit in the GAAP statements.
- Debt and risk factors. Any changes to borrowings and the risk factors section since the 10-K.
How an 8-K, a 10-Q and a 10-K differ. When the 10-Q is filed, the box at the top of this page links to it.
Sources
- Exhibit 99.1: press release and financial tables, filed Oct 30, 2026
- Form 8-K filing index on SEC EDGAR
- AbbVie Form 10-K for fiscal 2025
Common questions
When did AbbVie report Q3 2026 results?
AbbVie filed its Q3 2026 press release with the SEC on Oct 30, 2026, as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).
What were AbbVie's revenue and EPS for Q3 2026?
Net revenues was $17.4B, compared with $15.8B in Q3 2025. Diluted EPS was $2.37, compared with $0.10.
Has AbbVie filed its 10-Q for Q3 2026?
Not when this page was built. Companies file the 10-Q a few weeks after quarter end, by a deadline the SEC sets by company size. This page links to it once it is filed.
AbbVie company file → · AbbVie filings news · Learn
Disclosures
- Editor holdings in ABBV
- The editor holds no position in AbbVie (ABBV). As of Oct 25, 2026.
- Compensation
- Nobody paid for this page. No affiliate links.
- Sources
- AbbVie's own SEC filings, linked next to each number.
- Last updated
- Oct 30, 2026
A summary of a public filing for general education, the same for every reader. Not a recommendation to buy, sell or hold ABBV. It reports what the company said and doesn't compare the results with forecasts by anyone else.